- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01301677
Ultra Violet B Radiation (UVR) Study of Strontium Chloride Hexahydrate Hydrocortisone
Double-blind, Randomised, Active (Hydrocortisone) Controlled Study of the Effect of 10% w/v Strontium Chloride Hexahydrate on Ultraviolet B Radiation (UVR) Induced Signs of Inflammation (Erythema and Pain) in Healthy Volunteers
Study Overview
Status
Intervention / Treatment
Detailed Description
Subjects that signed the informed consent and are eligible to the study will be irradiated on the back to evaluate their individual minimal erythema dose (MED).
A training session (without study medication) will be performed in order to introduce subjects to the testing and rating procedures.
Subjects will come in within 28 days of screening to start the treatment period of the study.
For eligible subjects, three test areas oriented along the long axis of the back and different from the areas of MED determination will be defined for the evaluation of effects on pain and inflammation induced by UVR. The three areas will be irradiated with 2 MED. In addition, non-irradiated, not treated areas will serve as reference and training areas for the individual visits.
Topical treatments will be randomly assigned to the three test areas.
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Bavaria
-
Graefelfing, Bavaria, Germany, 82166
- X-pert Med GmbH
-
-
Thuringia
-
Jena, Thuringia, Germany, 07745
- X-pert Med GmbH
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed and dated informed consent prior to any study-mandated procedure
- Subjects in good health as determined by the Investigator
- Willing and able to comply with study requirements
- Age ≥ 18
- Fitzpatrick skin types I, II, or III
- Willing to avoid sun exposure, tanning lamps and use of any topical products on the test areas during the study
- Willing not to wash test areas during treatment period
- Willing to abstain from sauna, exposure to extreme cold or major physical activities during the treatment period of the study
- For females, subjects of childbearing potential (including peri-menopausal women who have had a menstrual period within 1 year) must be using appropriate birth control (defined as a method which results in a low failure rate, i.e., less than 1% per year when used consistently and correctly, such as implants, injectables, some intrauterine contraceptive devices (IUDs), sexual abstinence, or a vasectomized partner). Oral contraceptive medications are allowed in this study. Female subjects, who are surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy) are also allowed for participation
Exclusion Criteria:
General
- Planned treatment or treatment with another investigational drug within 30 days prior to randomization.
- Subjects who are inmates of psychiatric wards, prisons, or other state institutions
- Investigator or any other team member involved directly or indirectly in the conduct of the clinical study
- Pregnancy or lactation
- Any known factor or disease that might interfere with treatment compliance, study conduct or interpretation of the results such as drug or alcohol dependence or psychiatric disease.
Medical History
- Malignancy within the past 2 years with the exception of in situ removal of basal cell carcinoma
- Known hypersensitivity or allergy (including photoallergy) to hydrocortisone, strontium chloride hexahydrate, glycofurol, dimethylsulphoxide (DMSO), ethanol, propylene glycol, glycerol, hypomellose, sodium edentate, sodium hydroxide, citric acid monohydrate and metagin
- History of photosensitivity disease
- Sunburn, excessive tan, uneven skin tones or blemishes of the test areas
- Pain conditions which might interfere with pain rating during the study, e.g. neuropathic pain
- Open wounds, infection, inflammation or other dermal diseases of the intended application areas
- ALT or AST ≥ 5 times the ULN
- Glomerulary filtration rate < 30 ml/min
Medication History
- Systemic or topical drugs that might affect responses to UVR or interfere with responses to IMP including corticosteroids, thiazides, tetracyclines and NSAIDs must be washed out with 5 times half-life time prior to randomization to treatment
- Drugs with potential dermatologic adverse events defined by the respective summary of product characteristics (e.g. tetracyclines, gyrase inhibitors) must be washed out with 5 times half-life time prior to randomization to treatment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Hydrocortisone
|
Hydrocortisone liquid formulation
|
Experimental: 2PX+
strontium chloride hexahydrate in a penetration enhancing vehicle
|
strontium chloride hexahydrate in a penetration enhancing vehicle
|
Experimental: 2PX-
strontium chloride hexahydrate without a penetration enhancing vehicle
|
strontium chloride hexahydrate without a penetration enhancing vehicle
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Degree of erythema
Time Frame: at 6 h, 12 h, 24 h, 36 h, 48 h post UVR
|
at 6 h, 12 h, 24 h, 36 h, 48 h post UVR
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pain threshold (primary hyperalgesia to heat)
Time Frame: Sum of assessments at 6 h, 12 h, 24 h, 36 h, 48 h post UVR
|
Sum of assessments at 6 h, 12 h, 24 h, 36 h, 48 h post UVR
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Ilka Rother, MD, X-pert Med GmbH
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- XPM-033
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pain
-
Flowonix MedicalApproved for marketingBack Pain | Leg Pain | Trunk Pain | Intractable Pain | Arm Pain
-
University Hospital Schleswig-HolsteinZealand University Hospital; European Regional Development Fund; Design School...CompletedPain, Acute | Pain, Chronic | Pain Measurement | Pain, CancerGermany
-
Universitat Jaume ICompletedPain, Acute | Pain, Chronic | OncologySpain
-
Dow University of Health SciencesRecruitingLow Back Pain | Chronic Low-back Pain | Low Back Pain, Mechanical | Mechanical Low Back Pain | Pain, Chronic | Pain, Back | Lower Back Pain Chronic | CLBP - Chronic Low Back PainPakistan
-
Dr. Negrin University HospitalCompletedPostoperative Pain, Acute | Postoperative Pain, ChronicSpain
-
University of Campinas, BrazilCompletedPREGNANCY | LUMBAR BACK PAIN | PELVIC PAIN
-
George Washington UniversityRecruitingCervical Fusion | Pain, Back | Pain, Neck | Myofacial PainUnited States
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Postoperative Pain, Acute | Postoperative Pain, Chronic | VATSTurkey
-
Janssen Research & Development, LLCCompletedPain, Radiating | Pain, Burning | Pain, Crushing | Pain, Migratory | Pain, SplittingUnited States, France, Spain, Poland, Portugal
-
susanne beckerSNSFCompletedLow Back Pain | Pain, Acute | Pain, ChronicSwitzerland
Clinical Trials on Hydrocortisone
-
Assistance Publique - Hôpitaux de ParisCompletedBronchopulmonary DysplasiaFrance
-
Horus UniversityRecruitingSubacromial Impingement Syndrome | Impingement SyndromeEgypt
-
University Hospital Southampton NHS Foundation...Imperial College London; University of Bristol; University Hospitals Bristol... and other collaboratorsCompleted
-
Ulla Feldt-RasmussenUnknown
-
University of VersaillesAssistance Publique - Hôpitaux de ParisTerminatedPneumonia, Viral | Influenza in HumansFrance
-
Vastra Gotaland RegionSahlgrenska University Hospital, Sweden; The Gothenburg Society of Medicine; Åke... and other collaboratorsNot yet recruitingDiabetes Mellitus | Adrenal Insufficiency | Polyglandular Autoimmune SyndromeSweden
-
Central Institute of Mental Health, MannheimGerman Research FoundationCompletedPosttraumatic Stress DisorderGermany
-
Ludwig-Maximilians - University of MunichCompletedSystemic Inflammatory Response Syndrome | Posttraumatic Stress DisorderGermany
-
Jerry ZimmermanEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsRecruitingSeptic ShockUnited States, Canada, China, Israel, Japan, Malaysia, Pakistan, Saudi Arabia, Singapore, Vietnam
-
Haukeland University HospitalUnknownUltradian Subcutaneous Hydrocortisone Infusion in Addison Disease and Congenital Adrenal HyperplasiaAddison Disease | Adrenal Hyperplasia CongenitalNorway